Setlai, B.P.; Hull, R.; Bida, M.; Durandt, C.; Mulaudzi, T.V.; Chatziioannou, A.; Dlamini, Z.
Immunosuppressive Signaling Pathways as Targeted Cancer Therapies. Biomedicines 2022, 10, 682.
https://doi.org/10.3390/biomedicines10030682
AMA Style
Setlai BP, Hull R, Bida M, Durandt C, Mulaudzi TV, Chatziioannou A, Dlamini Z.
Immunosuppressive Signaling Pathways as Targeted Cancer Therapies. Biomedicines. 2022; 10(3):682.
https://doi.org/10.3390/biomedicines10030682
Chicago/Turabian Style
Setlai, Botle Precious, Rodney Hull, Meshack Bida, Chrisna Durandt, Thanyani Victor Mulaudzi, Aristotelis Chatziioannou, and Zodwa Dlamini.
2022. "Immunosuppressive Signaling Pathways as Targeted Cancer Therapies" Biomedicines 10, no. 3: 682.
https://doi.org/10.3390/biomedicines10030682
APA Style
Setlai, B. P., Hull, R., Bida, M., Durandt, C., Mulaudzi, T. V., Chatziioannou, A., & Dlamini, Z.
(2022). Immunosuppressive Signaling Pathways as Targeted Cancer Therapies. Biomedicines, 10(3), 682.
https://doi.org/10.3390/biomedicines10030682